Haemonetics
HAE
101.71
-1.81
-1.75%
Haemonetics
US · HAE
#2165 by market cap
Listed 1970
101.71
-1.81
-1.75%
Live - 5344 symbols - heartbeat 310s ago
· 2026-10-08 08:29
Pre-market
117.00
+15.03%
After-hours
101.71
0.00%
- Market cap
- 4.63B
- P/E (TTM)i
- 49.14
- P/Bi
- 5.53
- EPSi
- 2.05
- Div yieldi
- 0.00%
- 52W posi
- 86%
Reader sentiment
Are you bullish or bearish on HAE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 110.02% -0.34pp
- Institutions
- 394
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund86.01%
Hedge Fund13.99%
Public Company6.54%
Insurance Company2.07%
Individual/Insider1.30%
Government Pension Fund0.91%
Private Company0.23%
Sovereign Wealth Fund0.15%
Top holders as of 2026-06-30
BlackRock
12.99% · 5.91M sh
Neuberger Berman Investment Advisers LLC
9.19% · 4.18M sh
Vanguard Portfolio Management, LLC
5.60% · 2.55M sh
Vanguard Capital Management, LLC
5.25% · 2.39M sh
AQR Capital Management
4.95% · 2.25M sh
Ariel Investments, LLC
4.53% · 2.06M sh
State Street Global Advisors
4.00% · 1.82M sh
T. Rowe Price Group, Inc.
3.82% · 1.74M sh
Dimensional Fund Advisors
3.48% · 1.59M sh
Citadel Advisors LLC
3.32% · 1.51M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Christopher Simon | Chief Executive Officer | 0.76% |
| Michelle Basil | General Counsel | 0.08% |
| Robert Abernathy | Independent Director | 0.05% |
| Mark Kroll | Independent Director | 0.05% |
| Laurie Miller | Chief Human Resources Officer | 0.05% |
| Charles Dockendorff | Independent Director | 0.05% |
| Ellen Zane | Independent Chairperson | 0.04% |
| James D'Arecca | CFO, Executive VP & Financial Officer | 0.04% |
| Claire Pomeroy | Independent Director | 0.04% |
| Michael Coyle | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-23 | Robert Abernathy | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Michael Coyle | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Ellen Zane | Independent Chairperson | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Claire Pomeroy | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Mark Kroll | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Martin Madaus | Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Diane Bryant | Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Lloyd Johnson | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-06-04 | Laurie Miller | Chief Human Resources Officer | Sale to Issuer | -313 | $71.28 |
| 2026-06-04 | Farris Maryanne Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | Sale to Issuer | -259 | $71.28 |
| 2026-05-14 | Michelle Basil | General Counsel | Sale to Issuer | -2,913 | $56.29 |
| 2026-05-14 | Michelle Basil | General Counsel | Other Acquisition | +28,424 | -- |
| 2026-05-14 | Christopher Simon | Chief Executive Officer | Sale to Issuer | -9,681 | $56.29 |
| 2026-05-14 | Christopher Simon | Chief Executive Officer | Other Acquisition | +78,344 | -- |
| 2026-05-14 | James D'Arecca | CFO, Executive VP & Financial Officer | Sale to Issuer | -2,505 | $56.29 |
| 2026-05-14 | James D'Arecca | CFO, Executive VP & Financial Officer | Other Acquisition | +29,312 | -- |
| 2026-05-14 | Laurie Miller | Chief Human Resources Officer | Sale to Issuer | -948 | $56.29 |
| 2026-05-14 | Laurie Miller | Chief Human Resources Officer | Other Acquisition | +13,323 | -- |
| 2026-05-14 | Frank Chan | Chief Operating Officer | Sale to Issuer | -546 | $56.29 |
| 2026-05-14 | Frank Chan | Chief Operating Officer | Other Acquisition | +27,535 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:29:55 · For reference only, not investment advice and not tailored to your situation.